RESEARCH ARTICLE Differential expression of MAGEA6 toggles autophagy to promote pancreatic cancer progression Yiu Huen Tsang1,2*, Yumeng Wang3, Kathleen Kong1, Caitlin Grzeskowiak1, Oksana Zagorodna1, Turgut Dogruluk1, Hengyu Lu1, Nicole Villafane1,4, Venkata Hemanjani Bhavana1, Daniela Moreno1, Sarah H Elsea1, Han Liang3,5, Gordon B Mills2,5, Kenneth L Scott1† 1Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, United States; 2Cell, Develop & Cancer Biology, Oregon Health & Science University, Portland, United States; 3Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, United States; 4Michael E DeBakey Department of Surgery, Baylor College of Medicine, Houston, United States; 5Department of Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, United States Abstract The melanoma-associated antigen family A (MAGEA) antigens are expressed in a wide variety of malignant tumors but not in adult somatic cells, rendering them attractive targets for cancer immunotherapy. Here we show that a number of cancer-associated MAGEA mutants that undergo proteasome-dependent degradation in vitro could negatively impact their utility as immunotherapeutic targets. Importantly, in pancreatic ductal adenocarcinoma cell models, MAGEA6 suppresses macroautophagy (autophagy). The inhibition of autophagy is released upon MAGEA6 degradation, which can be induced by nutrient deficiency or by acquisition of cancer- associated mutations. Using xenograft mouse models, we demonstrated that inhibition of *For correspondence: autophagy is critical for tumor initiation whereas reinstitution of autophagy as a consequence of
[email protected] MAGEA6 degradation contributes to tumor progression. These findings could inform cancer immunotherapeutic strategies for targeting MAGEA antigens and provide mechanistic insight into †Deceased the divergent roles of MAGEA6 during pancreatic cancer initiation and progression.